FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to trispecific binding molecules which are multi-stranded polypeptide molecules, which have three binding domains and are thus capable of mediating coordinated binding with three epitopes.
EFFECT: trispecific binding molecule is preferably characterized by that it has binding domains which enable it to immunospecifically bind to: (1) an epitope of a first antigen of a malignant tumor, (2) an epitope of a second antigen of a malignant tumor, and (3) an epitope of the molecule, which is expressed on the surface of the effector cells of the immune system, and is thus able to localize the effector cell of the immune system with the cell, which expresses a malignant tumor antigen, so as to facilitate the destruction of such a malignant tumor cell.
26 cl, 10 dwg, 6 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BISPECIFIC BINDING MOLECULES CAPABLE OF BINDING CD137 AND TUMOR ANTIGENS AND VARIANTS OF THEIR APPLICATION | 2018 |
|
RU2805648C2 |
| VARIANT CD3 BINDING DOMAINS AND THEIR USE IN COMBINATION THERAPY FOR TREATMENT OF DISEASES | 2019 |
|
RU2810222C2 |
| ADAM9-BINDING MOLECULES AND THEIR APPLICATION METHODS | 2017 |
|
RU2783619C2 |
| TRIFUNCTIONAL ANTIGEN-BINDING MOLECULE | 2015 |
|
RU2753882C2 |
| IL-1 BINDING PROTEINS | 2011 |
|
RU2615173C2 |
| NEW PSMA-BINDING ANTIBODY AND ITS APPLICATIONS | 2017 |
|
RU2762704C2 |
| BISPECIFIC MOLECULES, IMMUNOREACTIVE WITH IMMUNE EFFECTOR CELLS EXPRESSING AN ACTIVATING RECEPTOR | 2014 |
|
RU2721707C2 |
| BISPECIFIC BINDING AGENTS WITH INTERSPECIFIC SPECIFICITY | 2008 |
|
RU2535992C2 |
| ANTIBODIES BINDING TO HLA-A2/WT1 | 2018 |
|
RU2815176C2 |
| HEAVY CHAIN-ONLY ANTIBODIES THAT BIND TO CD19 | 2019 |
|
RU2824170C2 |
